Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:07 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 7,078 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Gynecologic Cancer, Cancer-related Cognitive Difficulties
Interventions
Semiconductor embedded headband, Sham Headband
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Breast Cancer
Interventions
Relaxation and Visualization Therapy, Health education
Behavioral · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Conditions
HER2-Positive Early Breast Cancer
Interventions
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Lakewood, Colorado • Peoria, Illinois • Wichita, Kansas + 5 more
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Not applicable Interventional Results available

PET/CT Evaluation of Treatment Response in Breast Cancer

NCT01222416
Conditions
Breast Cancer
Interventions
Radiopharmaceutical Administration [18F]-FDG, Radiopharmaceutical: [18F]-FLT
Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Breast Cancer, Hot Flashes
Interventions
St. John's Wort
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Newark, Delaware • Washington D.C., District of Columbia • Miami, Florida + 16 more
Conditions
Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome
Interventions
ELISABETH Evidence-Informed Program (EIP)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

NCT03761914
Conditions
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions
galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Biological · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
12
States / cities
Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
Conditions
Breast Cancer
Interventions
ferumoxtran-10, magnetic resonance imaging, sentinel lymph node biopsy
Drug · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Richmond, Virginia
Not listed No phase listed Observational Accepts healthy volunteers

Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System

NCT00267449
Conditions
Breast Cancer
Interventions
SoftScan Optical Breast Imaging System
Device
Lead sponsor
ART Advanced Research Technologies Inc.
Industry
Eligibility
20 Years to 80 Years · Female only
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
3
States / cities
La Jolla, California • Stanford, California • Stuart, Florida
Conditions
Breast Cancer
Interventions
Acupuncture, Sham acupuncture
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Interventions
Copper Cu 64-DOTA-Trastuzumab, Magnetic Resonance Imaging, Positron Emission Tomography, Trastuzumab, Trastuzumab Deruxtecan
Other · Procedure · Device + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
19 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Green Bay, Wisconsin
Conditions
BRCA1/2 Negative
Interventions
Questionnaires
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Stage IV Breast Cancer
Interventions
carbon C 14 oxaliplatin, oxaliplatin, laboratory biomarker analysis
Radiation · Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Sacramento, California
Completed Not applicable Interventional Accepts healthy volunteers

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

NCT04330716
Conditions
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Metastatic Prostate Cancer
Interventions
Standard Genetic Counseling, Educational Video
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
6
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Milford, Massachusetts + 3 more
Conditions
Breast Cancer
Interventions
Mathematical modeling to predict response to chemotherapy
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Breast Cancer, Obesity
Interventions
metformin hydrochloride, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Anna Maria Storniolo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Malignant Neoplasm
Interventions
MK-4700, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Hackensack, New Jersey • San Antonio, Texas
Active, not recruiting Phase 1 Interventional

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216
Conditions
Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
Interventions
[18F]FLT, PET/CT, ribociclib, paclitaxel
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0405
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Carboplatin, Nab-paclitaxel, Pembrolizumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Breast Neoplasms
Interventions
prosocial online support group, Standard Online Support Group
Behavioral
Lead sponsor
Temple University
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania